XML 14 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows used in operating activities:    
Net loss $ (16,673) $ (9,075)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 300 524
Amortization of deferred financing costs and debt discount   20
Stock-based compensation expense 827 422
Noncash financing expenses 3,061 3,545
Change in fair value of derivative instruments 2,631 (5,654)
Accretion of discount on short-term investments (19) (70)
Reduction in the carrying amount of operating lease right-of-use assets 53 96
Gain on sale of assets (16)  
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Other assets 635 704
Accounts payable and accrued expenses (6,308) 1,326
Change in operating lease liabilities (54) (97)
Deferred grant liability 1,045 (1,084)
Net cash used in operating activities (14,518) (9,343)
Cash flows used in investing activities:    
Purchases of property and equipment (37) (135)
Proceeds from sale of property and equipment 30  
Purchase of short-term investments (11,068) (7,145)
Redemption of short-term investments 11,305 3,650
Purchase of intangible assets (7) (545)
Net cash provided by (used in) investing activities 223 (4,175)
Cash flows provided by financing activities:    
Principal payments of term loan obligation   (3,996)
Proceeds from credit facility   3,292
Repayment of credit facility (3,292)  
Payment of financing costs (2,250)  
Proceeds from issuance of notes payable and warrants 3,738  
Repayment of notes payable (3,703)  
Purchase of treasury stock   (374)
Proceeds from sale of common stock, pre-funded warrants and warrants 15,927 7,265
Proceeds from sale of common stock under Lincoln Park Purchase Agreement 19,612  
Payment to investors pursuant to Letter Agreement (Note 13) (2,293)  
Offering costs for sale of common stock (231)  
Net cash provided by financing activities 27,508 6,187
Net increase (decrease) in cash and cash equivalents 13,213 (7,331)
Cash and cash equivalents at beginning of period 76 8,554
Cash and cash equivalents at end of period 13,289 1,223
Cash paid during period for:    
Interest 539 $ 32
Supplemental schedule of non-cash investing and financing activities:    
Unpaid liability to investors pursuant to Letter Agreement (Note 13) 6,391  
Exchange of warrants for notes payable 3,694  
Redemption of notes by issuance of common stock, pre-funded warrants and warrants 3,512  
Unpaid offering cost $ 252